Cincinnati, OH – According to filings with the U.S. Securities and Exchange Commission, Enable Injections is raising $215,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Hooven played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Enable Injections
Enable Injections is committed to developing and manufacturing innovative drug delivery systems that satisfy Customer and Regulatory requirements, and to maintain the effectiveness of the Quality Management System. Enable Injections uses human factors, the examination of the relationship between human beings and the systems with which they interact, to guide the design of the enFuse platform. The goal is to provide a product that users prefer and can use safely and effectively to administer their injectable therapies. This goal is achieved through an iterative design and evaluation process where use errors are investigated, root causes identified, and mitigations implemented until the likelihood of use errors has been reduced to the greatest extent possible. At Enable Injections, patient insights drive us to continuously explore ways to improve the patient experience, increase patient safety, and reduce the healthcare burden. The enFuse delivery system is an innovative product designed to benefit patients, physicians, payers, and society.

To learn more about Enable Injections, visit http://enableinjections.com/

Contact:
Michael Hooven, Chief Executive Officer
513-326-2800
https://www.linkedin.com/in/mike-hooven-507ab614/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved